SCHEMBL9924073

SCHEMBL9924073

O=C(/N=C(/NC1CCCCC1)N[C@H]1CC[C@H](Nc2ncccn2)CC1)c1ccc(F)c(F)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MCHR1 Q99705 8/20 0.46
KDM4E B2RXH2 1/20 0.46
GAA P10253 1/20 0.46
ADRA2A P08913 2/20 0.43
ADRA1A P35348 2/20 0.43
HRH1 P35367 2/20 0.43
HTR2B P41595 2/20 0.43
HTR1A P08908 1/20 0.43
NPY5R Q15761 1/20 0.43
NPC1 O15118 2/20 0.42
RAB9A P51151 2/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
KCNQ3 O43525 1/20 0.42
KCNQ2 O43526 1/20 0.42
AR P10275 2/20 0.40
HDAC6 Q9UBN7 2/20 0.39
HDAC3 O15379 1/20 0.39
HDAC1 Q13547 1/20 0.39
HDAC2 Q92769 1/20 0.39
TAS1R3 Q7RTX0 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17206686 0.91 MCHR1 (0.48) MCHR1ADRA2AADRA1AHRH1HTR2B
SCHEMBL9924252 0.90 PDE4B (0.42) MCHR1KDM4EGAAADRA2AADRA1A
SCHEMBL17206701 0.84 MCHR1 (0.44) MCHR1ADRA2AADRA1AHRH1HTR2B
SCHEMBL9924422 0.84 KCNQ3 (0.42) MCHR1KDM4EADRA2AADRA1AHRH1
SCHEMBL9924233 0.84 KMT2A (0.49) MCHR1ADRA2AADRA1AHRH1HTR2B
SCHEMBL9900854 0.83 KCNQ3 (0.41) MCHR1ADRA2AADRA1AHRH1HTR2B
SCHEMBL9901952 0.83 KCNQ3 (0.41) MCHR1ADRA2AADRA1AHRH1HTR2B
SCHEMBL17206691 0.83 KCNQ3 (0.41) MCHR1ADRA2AADRA1AHRH1HTR2B
SCHEMBL9900852 0.83 KCNQ3 (0.41) MCHR1ADRA2AADRA1AHRH1HTR2B
SCHEMBL9924234 0.83 EPHX2 (0.41) MCHR1ADRA2AADRA1AHRH1HTR2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9169199-B2 Cycloalkyl guanidine F1F0-ATPase inhibitors and therapeutic uses thereof LYCERA CORPORATION (US) 2015-10-27 US disclosed
WO-2012078867-A2 CYCLOALKYL GUANIDINE F1F0-ATPASE INHIBITORS AND THERAPEUTIC USES THEREOF LYCERA CORPORATION (US) 2012-06-14 WO disclosed